$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000114420417041727 Filed on August 09, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$2.520M	$4.404M	$2.230M
YoY Change	158.46%	97.49%
Cost Of Revenue	$505.0K	$878.0K	$324.0K
YoY Change	1131.71%	170.99%
Gross Profit	$2.015M	$3.526M	$1.906M
YoY Change	115.74%	84.99%
Gross Profit Margin	79.96%	80.06%	85.47%
Selling, General & Admin	$15.10M	$11.13M	$8.635M
YoY Change	70.4%	28.94%	90.62%
% of Gross Profit	749.58%	315.77%	453.04%
Research & Development	$0.00	$1.800M	$2.060M
YoY Change	-100.0%	-12.62%	-14.56%
% of Gross Profit	0.0%	51.05%	108.08%
Depreciation & Amortization	$200.0K	$180.0K	$82.00K
YoY Change	0.0%	119.51%	1540.0%
% of Gross Profit	9.93%	5.1%	4.3%
Operating Expenses	$79.49M	$73.89M	$17.37M
YoY Change	361.58%	325.49%	123.73%
Operating Profit	-$31.80M	-$25.50M	-$17.04M
YoY Change	85.09%	49.6%	119.56%
Interest Expense	$3.220M	$1.380M	$529.0K
YoY Change	367.34%	160.87%	50.28%
% of Operating Profit
Other Income/Expense, Net	-$3.704M	$244.0K	-$1.253M
YoY Change	421.69%	-119.47%	-193.23%
Pretax Income	-$36.31M	-$22.95M	-$16.39M
YoY Change	114.07%	40.02%	155.3%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$27.12M	-$17.37M	-$12.48M
YoY Change	108.89%	39.16%	102.07%
Net Earnings / Revenue	-1076.03%	-394.3%	-559.55%
Basic Earnings Per Share
Diluted Earnings Per Share	-$666.0K	-$428.4K	-$313.0K
COMMON SHARES
Basic Shares Outstanding	50.53M shares	50.33M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$156.2M	$167.8M	$71.30M
YoY Change	84.42%	135.34%	7.05%
Cash & Equivalents	$128.5M	$161.2M	$71.34M
Short-Term Investments	$45.70M	$23.40M
Other Short-Term Assets	$11.70M	$12.90M	$1.600M
YoY Change	108.93%	706.25%	60.0%
Inventory	$318.0K	$299.0K	$100.0K
Prepaid Expenses
Receivables	$5.582M	$3.336M	$967.0K
Other Receivables	$10.20M	$5.900M	$2.500M
Total Short-Term Assets	$184.1M	$190.2M	$76.60M
YoY Change	86.7%	148.28%	23.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.397M	$7.329M	$4.500M
YoY Change	105.93%	62.87%	4900.0%
Goodwill	$18.65M	$18.65M
YoY Change	-14.23%
Intangibles
YoY Change
Long-Term Investments	$0.00	$300.0K	$250.0K
YoY Change	-100.0%	20.0%	0.0%
Other Assets	$346.0K	$16.30M	$14.60M
YoY Change	620.83%	11.64%	8388.37%
Total Long-Term Assets	$61.00M	$59.62M	$21.46M
YoY Change	30.29%	177.79%	-0.94%
TOTAL ASSETS
Total Short-Term Assets	$184.1M	$190.2M	$76.60M
Total Long-Term Assets	$61.00M	$59.62M	$21.46M
Total Assets	$245.1M	$249.8M	$98.06M
YoY Change	68.54%	154.74%	17.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$32.00M	$25.00M	$5.100M
YoY Change	46.79%	390.2%	774.79%
Accrued Expenses	$16.65M	$12.37M	$8.500M
YoY Change	93.5%	45.56%	93.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.00M	$6.200M
YoY Change
Total Short-Term Liabilities	$68.43M	$53.50M	$14.30M
YoY Change	77.31%	274.13%	186.29%
LONG-TERM LIABILITIES
Long-Term Debt	$50.70M	$40.70M	$21.80M
YoY Change	85.04%	86.7%	-6.03%
Other Long-Term Liabilities	$4.736M	$5.026M	$3.700M
YoY Change	3.34%	35.84%	1301.52%
Total Long-Term Liabilities	$4.736M	$5.026M	$25.50M
YoY Change	3.34%	-80.29%	9559.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$68.43M	$53.50M	$14.30M
Total Long-Term Liabilities	$4.736M	$5.026M	$25.50M
Total Liabilities	$123.8M	$99.23M	$62.70M
YoY Change	75.44%	58.26%	120.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$301.7M	-$274.6M
YoY Change	32.44%
Common Stock	$51.00K	$800.0K
YoY Change	4.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.94M	$72.27M	$35.34M
YoY Change
Total Liabilities & Shareholders Equity	$245.1M	$249.8M	$98.10M
YoY Change	68.54%	154.69%	17.21%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$27.12M	-$17.37M	-$12.48M
YoY Change	108.89%	39.16%	102.07%
Depreciation, Depletion And Amortization	$200.0K	$180.0K	$82.00K
YoY Change	0.0%	119.51%	1540.0%
Cash From Operating Activities	-$25.08M	-$23.88M	-$7.380M
YoY Change	184.35%	223.58%	19.81%
INVESTING ACTIVITIES
Capital Expenditures	-$550.0K	-$190.0K	-$2.160M
YoY Change	-62.33%	-91.2%	4220.0%
Acquisitions
YoY Change
Other Investing Activities	-$24.29M	-$20.03M	-$2.060M
YoY Change	-770.99%	872.33%	21.18%
Cash From Investing Activities	-$24.83M	-$20.23M	-$4.220M
YoY Change	-1249.54%	379.38%	141.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$34.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.14M	54.42M	1.520M
YoY Change	-4.03%	3480.26%	4966.67%
NET CHANGE
Cash From Operating Activities	-25.08M	-23.88M	-7.380M
Cash From Investing Activities	-24.83M	-20.23M	-4.220M
Cash From Financing Activities	17.14M	54.42M	1.520M
Net Change In Cash	-32.77M	10.31M	-10.08M
YoY Change	-392.59%	-202.28%	27.92%
FREE CASH FLOW
Cash From Operating Activities	-$25.08M	-$23.88M	-$7.380M
Capital Expenditures	-$550.0K	-$190.0K	-$2.160M
Free Cash Flow	-$24.53M	-$23.69M	-$5.220M
YoY Change	233.29%	353.83%	-14.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	190000	USD
CY2017Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	39274000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	22528000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5026000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5014000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	99230000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	87763000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	346630000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	283697000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-274598000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245251000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	72271000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	38495000	USD
CY2017Q2	us-gaap	Minority Interest MinorityInterest	78345000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	44473000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	150616000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	82968000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	170731000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	249846000	USD
CY2017Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	91000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	481000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3336000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1830000	USD
CY2017Q2	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1040000	USD
CY2016Q4	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1030000	USD
CY2017Q2	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	2813000	USD
CY2016Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	3357000	USD
CY2017Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1397000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1712000	USD
CY2017Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	3406000	USD
CY2016Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	2357000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	299000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	203000	USD
CY2017Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24995000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23871000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11613000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11940000	USD
CY2017Q2	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	891000	USD
CY2016Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	995000	USD
CY2017Q2	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	77000	USD
CY2016Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	298000	USD
CY2017Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	3007000	USD
CY2016Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1000000	USD
CY2017Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3211000	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1031000	USD
CY2017Q2	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	0	USD
CY2016Q4	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	1682000	USD
CY2017Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	217000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	319000	USD
CY2017Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1462000	USD
CY2016Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	3656000	USD
	us-gaap	Operating Expenses OperatingExpenses	136149000	USD
	us-gaap	Operating Expenses OperatingExpenses	33117000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40770000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30227000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	326000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	152000	USD
	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	2078000	USD
	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	1149000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5794000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	89000	USD
	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-285000	USD
	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	0	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	73890000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	17366000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23193000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15136000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	77000	USD
CY2017Q2	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	157000	USD
CY2016Q2	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-801000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	244000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1253000	USD
CY2017Q2	us-gaap	Profit Loss ProfitLoss	-22949000	USD
CY2016Q2	us-gaap	Profit Loss ProfitLoss	-16389000	USD
CY2017Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5584000	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3911000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-17365000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-12478000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40551844	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39867724	shares
CY2017Q2	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	1380000	USD
CY2016Q2	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	529000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1452000	USD
CY2016Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q2	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-188000	USD
CY2016Q2	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	7736000	USD
	fbio	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	USD
	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	1712000	USD
	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	92991000	USD
	fbio	Adjustments To Additional Paid In Capital Debt Discount Related To Opus Credit Facility AdjustmentsToAdditionalPaidInCapitalDebtDiscountRelatedToOpusCreditFacility	201000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	702000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	423000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7736000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5889000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3122000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-35369000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19019000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	454000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4300000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	350000	USD
	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	3000	USD
	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-21165000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6921000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2590000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-195000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	3000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2143000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	665000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	2095000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3095000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	267000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	21000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1506000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	967000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	96000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	100000	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-185000	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	2414000	USD
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	175000	USD
	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	362000	USD
	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	0	USD
	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	-104000	USD
	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	256000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-5794000	USD
	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	89000	USD
	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	-544000	USD
	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	0	USD
	fbio	Payment Of Nsc Note PaymentOfNscNote	2792000	USD
	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	47000	USD
	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	0	USD
	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	1049000	USD
	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	0	USD
	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	-221000	USD
	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	0	USD
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	259000	USD
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	19000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	93853000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	570000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	862000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
	fbio	Payment Of Nsc Note PaymentOfNscNote	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	112584000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-906000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	56050000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-26846000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98182000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71336000	USD
	us-gaap	Interest Paid InterestPaid	58000	USD
	us-gaap	Interest Paid InterestPaid	158000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	819000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15172000	USD
CY2014Q1	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.35	pure
CY2017Q2	us-gaap	Equity Method Investments EquityMethodInvestments	300000	USD
	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	500000	USD
CY2016Q4	fbio	Equity Securities Called By Warrant EquitySecuritiesCalledByWarrant	10000	USD
CY2017Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	903000	USD
CY2017Q2	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	903000	USD
CY2017Q2	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	4764000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3094000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2143000	USD
CY2017Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1800000	USD
CY2016Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2060000	USD
CY2017Q2	us-gaap	Long Term Debt LongTermDebt	51677000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	30224000	USD
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4723000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2009000	USD
CY2017Q2	us-gaap	Notes Payable NotesPayable	46954000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	28215000	USD
	us-gaap	Interest Expense InterestExpense	2078000	USD
	us-gaap	Interest Expense InterestExpense	1149000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	1380000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	529000	USD
CY2017Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2295000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2846000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1748000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1253000	USD
CY2017Q2	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	2914000	USD
CY2016Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	394000	USD
CY2017Q2	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	0	USD
CY2016Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	900000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2564000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12373000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10082000	USD
CY2017Q2	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	0	USD
CY2017Q2	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2852000	USD
CY2016Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2634000	USD
CY2017Q2	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5026000	USD
CY2016Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5014000	USD
CY2016Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	53000	USD
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	86509000	USD
CY2016	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	60668000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-16195000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14707298	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12348653	shares
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	7736000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	5889000	USD
CY2017Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4807000	USD
CY2016Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3023000	USD
CY2017Q2	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2017Q1	fbio	Warrants Issued WarrantsIssued	853677	shares
	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	200000	USD
CY2017Q2	us-gaap	Revenues Revenues	50697000	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	878000	USD
CY2017Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2610000	USD
CY2017Q2	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	13483000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8524000	USD
	us-gaap	Revenues Revenues	95379000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1347000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4877000	USD
	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	21887000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16509000	USD
CY2016Q2	us-gaap	Revenues Revenues	2230000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	324000	USD
CY2016Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1998000	USD
CY2016Q2	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	8407000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6637000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	FBIO
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50527604	shares
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50463245	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50463245	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48932023	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48932023	shares
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	750000	USD
	us-gaap	Depreciation Depreciation	543000	USD
	us-gaap	Depreciation Depreciation	74000	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	434000	USD
	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	0	USD
	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	49000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1939000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	42000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	81000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1000000	USD
	fbio	Annual Management Services Agreement Fee Incomeexpense AnnualManagementServicesAgreementFeeIncomeexpense	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15991000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1130501	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1110501	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1085501	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.73
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.78
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.75
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	602451000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1826461000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y11M5D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y5M16D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y5M5D
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0114	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0225	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9525	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0595	pure
CY2017Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	40000	USD
CY2016Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	30000	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	75000	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	56000	USD
	us-gaap	Revenues Revenues	2890000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	324000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3884000	USD
	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	16243000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12666000	USD
CY2016Q2	us-gaap	Assets Assets	98062000	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	20038000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2017Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	78000	USD
CY2017Q2	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	326000	USD
CY2016Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	77000	USD
CY2017Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	189000	USD
CY2016Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2017Q2	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	45818	shares
CY2016Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0	shares
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2017Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	13000	USD
CY2016Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	13000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	189000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	fbio	Increase Decrease In Cash Deposits With Clearing Organisations IncreaseDecreaseInCashDepositsWithClearingOrganisations	-10000	USD
	fbio	Increase Decrease In Cash Deposits With Clearing Organisations IncreaseDecreaseInCashDepositsWithClearingOrganisations	0	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	24000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	20038000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	1000	USD
	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	0	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	8000	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable		USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	18967000	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	USD
	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	2500000	USD
	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000	USD
	fbio	Promissory Notes Conversion Converted Instrument Amount PromissoryNotesConversionConvertedInstrumentAmount	1197000	USD
	fbio	Promissory Notes Conversion Converted Instrument Amount PromissoryNotesConversionConvertedInstrumentAmount	0	USD
	fbio	Convertible Notes Conversion Converted Instrument Amount ConvertibleNotesConversionConvertedInstrumentAmount	0	USD
	fbio	Convertible Notes Conversion Converted Instrument Amount ConvertibleNotesConversionConvertedInstrumentAmount	99000	USD
	fbio	Licence Conversion Converted Instrument Amount LicenceConversionConvertedInstrumentAmount	0	USD
	fbio	Licence Conversion Converted Instrument Amount LicenceConversionConvertedInstrumentAmount	48000	USD
	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	1682000	USD
	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	0	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	314000	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	42000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	211000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
	fbio	Noncash Or Part Noncash Acquisition Net Nonmonetary Identifiable Intangible Assets Acquired Liabilities Assumed NoncashOrPartNoncashAcquisitionNetNonmonetaryIdentifiableIntangibleAssetsAcquiredLiabilitiesAssumed	0	USD
	fbio	Noncash Or Part Noncash Acquisition Net Nonmonetary Identifiable Intangible Assets Acquired Liabilities Assumed NoncashOrPartNoncashAcquisitionNetNonmonetaryIdentifiableIntangibleAssetsAcquiredLiabilitiesAssumed	19000	USD
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1414000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	1414000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	5168000	USD
	fbio	Issuance Of Warrants In Conjunction With Nsc Debt IssuanceOfWarrantsInConjunctionWithNscDebt	0	USD
	fbio	Issuance Of Warrants In Conjunction With Nsc Debt IssuanceOfWarrantsInConjunctionWithNscDebt	750000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	201000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	79000	USD
	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1721000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3571000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	192000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	20941000	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	13857000	USD
	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	5794000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	285000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-511000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1064000	USD
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	300000	USD
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	47949	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.02
CY2017Q2	fbio	Exercise Price Of Warrant Discount Percentage ExercisePriceOfWarrantDiscountPercentage	0.33	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	67600000	USD
CY2017Q2	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	20000000	USD
CY2017Q2	fbio	Short Term Investment Maximum Amount Per Institution ShortTermInvestmentMaximumAmountPerInstitution	250000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	42000	USD
	fbio	Adjustments To Additional Paid In Capital Warrants Issued In Connection With Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithPromissoryNotes	1197000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	314000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	180000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	82000	USD
	fbio	Common Shares Issuable For Interest Payable CommonSharesIssuableForInterestPayable	189000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1826461	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3200000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2400000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20000	shares
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1826461000	USD
CY2017Q2	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1605000	USD
CY2016Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1790000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11902000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9061000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	190180000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	109634000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	630000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	424000	USD
CY2017Q2	fbio	Warrants Issuable Current WarrantsIssuableCurrent	8190000	USD
CY2016Q4	fbio	Warrants Issuable Current WarrantsIssuableCurrent	14359000	USD
	fbio	Change In Fair Value Of Subsidiaries Assets And Liabilities ChangeInFairValueOfSubsidiariesAssetsAndLiabilities	10000	USD
	fbio	Change In Fair Value Of Subsidiaries Assets And Liabilities ChangeInFairValueOfSubsidiariesAssetsAndLiabilities	249000	USD
	fbio	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantedWeightedAverageRemainingContractualTerm	P9Y9M22D
	fbio	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm	P9Y9M22D
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7329000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7376000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15860000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15860000	USD
CY2017Q2	us-gaap	Long Term Investments LongTermInvestments	903000	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	1414000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16533000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17408000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	18645000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	18645000	USD

Files In Submission

Name	View Source	Status
0001144204-17-041727-index-headers.html	Edgar Link	pending
0001144204-17-041727-index.html	Edgar Link	pending
0001144204-17-041727.txt	Edgar Link	pending
0001144204-17-041727-xbrl.zip	Edgar Link	pending
fbio-20170630.xml	Edgar Link	completed
fbio-20170630.xsd	Edgar Link	pending
fbio-20170630_cal.xml	Edgar Link	unprocessable
fbio-20170630_def.xml	Edgar Link	unprocessable
fbio-20170630_lab.xml	Edgar Link	unprocessable
fbio-20170630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v472044_10q.htm	Edgar Link	pending
v472044_ex31-1.htm	Edgar Link	pending
v472044_ex31-2.htm	Edgar Link	pending
v472044_ex32-1.htm	Edgar Link	pending
v472044_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2017 Q3 Form 10-Q Financial Statement

#000114420417041727 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2017 Q3 Form 10-Q Financial Statement

#000114420417041727 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio